Activation of TAFI on the Surface of Streptococcus pyogenes Evokes Inflammatory Reactions by Modulating the Kallikrein/Kinin System

被引:33
作者
Bengtson, Sara H. [1 ]
Sanden, Caroline [2 ]
Morgelin, Matthias [1 ]
Marx, Pauline F. [3 ,4 ]
Olin, Anders I. [1 ]
Leeb-Lundberg, L. M. Fredrik [2 ]
Meijers, Joost C. M. [3 ,4 ]
Herwald, Heiko [1 ]
机构
[1] Lund Univ, Dept Clin Sci, Sect Clin & Expt Infect Med, SE-22184 Lund, Sweden
[2] Lund Univ, Dept Expt Med Sci, Unit Drug Target Discovery, SE-22184 Lund, Sweden
[3] Univ Amsterdam, Acad Med Ctr, Dept Vasc, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1105 AZ Amsterdam, Netherlands
基金
瑞典研究理事会;
关键词
Proteolysis; Hemostasis; Thrombosis; Vascular biology; Phagocytes; FIBRINOLYSIS INHIBITOR; CONTACT SYSTEM; HUMAN PLASMA; M-PROTEIN; BRADYKININ; RELEASE; INACTIVATION; GENERATION; FIBRINOGEN; RECEPTORS;
D O I
10.1159/000145543
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Bacteria-controlled regulation of host responses to infection is an important virulence mechanism that has been demonstrated to contribute to disease progression. Here we report that the human pathogen Streptococcus pyogenes employs the procarboxypeptidase TAR (thrombin-activatablefibrinolysis inhibitor) to modulate the kallikrein/kinin system. To this end, bacteria initiate a chain of events starting with the recruitment and activation of TAFI. This is followed by the assembly and induction of the contact system at the streptococcal surface, eventually triggering the release of bradykinin (BK). BK is then carboxyterminally truncated by activated TAFI, which converts the peptide from a kinin B-2 receptor ligand to a kinin B-1 receptor (B1R) agonist. Finally, we show that streptococcal supernatants indirectly amplify the B1R response as they act on peripheral blood mononuclear cells to secrete inflammatory cytokines that in turn stimulate upregulation of the B1R on human fibroblasts. Taken together our findings implicate a critical and novel role for streptococci-bound TAR, as it processes BK to a B1R agonist at the bacterial surface and thereby may redirect inflammation from a transient to a chronic state. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:18 / 28
页数:11
相关论文
共 33 条
[1]
Staphylococcal and streptococcal superantigens:: molecular, biological and clinical aspects [J].
Alouf, JE ;
Müller-Alouf, H .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 292 (7-8) :429-440
[2]
Kinin receptor expression during Staphylococcus aureus infection [J].
Bengtson, Sara H. ;
Phagoo, Stephen B. ;
Norrby-Teglund, Anna ;
Pahlman, Lisa ;
Morgelin, Matthias ;
Zuraw, Bruce L. ;
Leeb-Lundberg, L. M. Fredrik ;
Herwald, Heiko .
BLOOD, 2006, 108 (06) :2055-2063
[3]
Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin [J].
BenNasr, A ;
Herwald, H ;
Sjobring, U ;
Renne, T ;
MullerEsterl, W ;
Bjorck, L .
BIOCHEMICAL JOURNAL, 1997, 326 :657-660
[4]
HUMAN KININOGENS INTERACT WITH M-PROTEIN, A BACTERIAL SURFACE PROTEIN AND VIRULENCE DETERMINANT [J].
BENNASR, A ;
HERWALD, H ;
MULLERESTERL, W ;
BJORCK, L .
BIOCHEMICAL JOURNAL, 1995, 305 :173-180
[5]
An integrated study of fibrinogen during blood coagulation [J].
Brummel, KE ;
Butenas, S ;
Mann, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (32) :22862-22870
[6]
Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N [J].
Campbell, WD ;
Lazoura, E ;
Okada, N ;
Okada, H .
MICROBIOLOGY AND IMMUNOLOGY, 2002, 46 (02) :131-134
[7]
The global burden of group A streptococcal diseases [J].
Carapetis, JR ;
Steer, AC ;
Mulholland, EK ;
Weber, M .
LANCET INFECTIOUS DISEASES, 2005, 5 (11) :685-694
[8]
Pathogenesis of group A streptococcal infections [J].
Cunningham, MW .
CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (03) :470-+
[9]
Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis [J].
Enquist, Johan ;
Skroder, Carl ;
Whistler, Jennifer L. ;
Leeb-Lundberg, M. Fredrik .
MOLECULAR PHARMACOLOGY, 2007, 71 (02) :494-507
[10]
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127) - Results of a randomized, double-blind, placebo-controlled trial [J].
Fein, AM ;
Bernard, GR ;
Criner, GJ ;
Fletcher, EC ;
Good, JT ;
Knaus, WA ;
Levy, H ;
Matuschak, GM ;
Shanies, HM ;
Taylor, RW ;
Rodell, TC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (06) :482-487